Spots Global Cancer Trial Database for A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Official Title: A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study ID: NCT02220842
Conditions
Study Description
Brief Summary: This open-label, multicenter, global study is designed to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of intravenous atezolizumab (MPDL3280A) and obinutuzumab in participants with refractory or relapsed follicular lymphoma (FL) or atezolizumab and obinutuzumab or tazemetostat administered in participants with refractory or relapsed diffuse large B-cell lymphoma (DLBCL). The anticipated duration of this study is approximately 4.5 years.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
UW- Fred Hutchinson Cancer Center, Seattle, Washington, United States
Hopital Claude Huriez - CHU Lille; Service des maladies du sang, Lille, , France
Hopital Saint Eloi, Montpellier, , France
Hôpital Saint-Louis, Paris, , France
Centre Hospitalier Lyon Sud, Pierre Benite, , France
Institut Gustave Roussy, Villejuif, , France
Universitaetsklinikum Freiburg, Freiburg, , Germany
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy
Barts Hospital, London, , United Kingdom
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
